() Carprieve Injection | Norbrook Laboratories

Carprieve Injection

Carprieve Injection is a solution for injection, containing 50 mg carprofen per mL. Part of the non-steroidal anti-inflammatory drug group it is an analgesic for the relief of pain and inflammation in dogs, cats and horses.

Target Species: Dogs, cats and horses

  • Active Ingredient

    50 mg carprofen/mL

  • Pharmaceutical Form

    Solution for injection

  • Indications

    This product is indicated for the control of post-operative pain and inflammation following surgery in dogs, cats and horses and the alleviation of pain and inflammation associated with musculo-skeletal disorders in horses.

  • Dosage

    Dogs: For intravenous and subcutaneous use. Dose rate is 4.0 mg/kg (1mL/12.5 kg) bodyweight Carprieve Injection is best given pre-operatively, either at the time of pre-medication or induction of anaesthesia. Cats: For intravenous and subcutaneous use as a single dose. Dose rate is 4.0 mg/kg (0.24 mL/3.0 kg). Carprieve Injection is best given pre-operatively, either at the time of pre-medication or induction of anaesthesia. The use of an insulin syringe is recommended to measure the dose accurately. Horses: For intravenous use only. Dose rate is 0.7 mg/kg (1mL/70 kg) bodyweight. Carprieve Injection should be given by intravenous injection as a single dose. The dose may be repeated after 24 hours and then daily for a total treatment period of up to 5 days.

Prefer to speak directly to a member of our team?

Norbrook Laboratories Australia Pty Ltd.

We are open Mon - Fri 9:00am - 5:00pm

Please note: Product information presented on this website is intended only as a brief summary of Norbrook products for your convenience. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information you should always consult a healthcare professional from your region or visit the local government agency website for the most up to date information. Please see our terms and conditions for further information.